Literature DB >> 3414517

Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation.

M Shenasa1, T Kus, M Fromer, R A LeBlanc, M Dubuc, R Nadeau.   

Abstract

Both verapamil and diltiazem are used to control ventricular response during atrial fibrillation (AF). Their effect on the maintenance of AF is not known. The effects of the intravenous and oral administration of verapamil and diltiazem were investigated in 35 patients, 18 with (group I) and 17 without (group II) documented paroxysmal AF. Programmed electrical stimulation, either extra-stimuli or burst atrial pacing, was used to induce AF. In group I, the mean values of the duration of AF before and after the intravenous and oral administration of the calcium antagonists were 31 +/- 12, 112 +/- 49 and 69 +/- 25 minutes, respectively. For group II, the values were 5 +/- 3.4, 39 +/- 13 and 14 +/- 7 minutes, respectively. The differences were statistically highly significant (p less than 0.001), after both oral and intravenous administration compared with the baseline value in both groups. The data suggest that both intravenously and orally administered calcium antagonists enhance sustenance of electrically induced AF, especially in patients with spontaneous arrhythmia. Thus, in patients with paroxysmal AF, verapamil or diltiazem should be administered cautiously, because these drugs may prolong the duration of arrhythmia. Further studies are warranted to investigate the role of calcium antagonists in spontaneously occurring paroxysmal AF.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3414517     DOI: 10.1016/0002-9149(88)90967-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

Review 1.  Atrial fibrillation. The therapeutic options.

Authors:  R V Lewis
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Effect of verapamil on tachycardia-induced early cellular electrical remodeling in rabbit atrium.

Authors:  Roman Laszlo; Christoph Winkler; Stefan Wöhrl; Ralf E Wessel; Sara Laszlo; Mathias C Busch; Jürgen Schreieck; Ralph F Bosch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-15       Impact factor: 3.000

3.  Influence of verapamil on tachycardia-induced alterations of PP1 and PP2A in rabbit atrium.

Authors:  Roman Laszlo; Christoph Winkler; Stefan Wöhrl; Sara Laszlo; Christian Eick; Jürgen Schreieck; Ralph F Bosch
Journal:  Exp Clin Cardiol       Date:  2007

4.  Atrial electrical remodeling by rapid pacing in the isolated rabbit heart: effects of Ca++ and K+ channel blockade.

Authors:  M A Wood; D Caponi; A M Sykes; E J Wenger
Journal:  J Interv Card Electrophysiol       Date:  1998-03       Impact factor: 1.900

5.  Management of Atrial Fibrillation: Identifying and treating the causes.

Authors:  S W Rabkin
Journal:  Can Fam Physician       Date:  1991-03       Impact factor: 3.275

Review 6.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 7.  The pharmacologic treatment of atrial fibrillation.

Authors:  R Bolognesi
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

8.  Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil.

Authors:  C-J A Lindholm; O Fredholm; S-J Möller; N Edvardsson; T Kronvall; T Pettersson; V Firsovaite; A Roijer; C J Meurling; P G Platonov; S B Olsson
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

9.  Intravenous propafenone: efficacy and safety in the conversion to sinus rhythm of recent onset atrial fibrillation--a single-blind placebo-controlled study.

Authors:  F Bellandi; R P Dabizzi; F Cantini; M D Natale; L Niccoli
Journal:  Cardiovasc Drugs Ther       Date:  1996-05       Impact factor: 3.727

Review 10.  The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations.

Authors:  S Nattel; T Hadjis; M Talajic
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.